help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Published ahead of print on March 24, 2004, doi:10.1164/rccm.200312-1670OC
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Online Supplement
Right arrow All Versions of this Article:
200312-1670OCv1
170/2/133    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Strieter, R. M.
Right arrow Articles by the other members of the Idiopathic Pulmonary Fibrosis Biomarkers Study Group
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Strieter, R. M.
Right arrow Articles by the other members of the Idiopathic Pulmonary Fibrosis Biomarkers Study Group,
American Journal of Respiratory and Critical Care Medicine Vol 170. pp. 133-140, (2004)
© 2004 American Thoracic Society

Original Article

Effects of Interferon-{gamma} 1b on Biomarker Expression in Patients with Idiopathic Pulmonary Fibrosis

Robert M. Strieter, Karen M. Starko, Richard I. Enelow, Imre Noth, Vincent G. Valentine and the other members of the Idiopathic Pulmonary Fibrosis Biomarkers Study Group

David Geffen School of Medicine at the University of California at Los Angeles, Los Angeles; InterMune, Inc., Brisbane, California; University of Virginia Medical Center, Charlottesville, Virginia; University of Chicago, Chicago, Illinois; Ochsner Clinic Foundation, New Orleans, Louisiana

Correspondence and requests for reprints should be addressed to Robert M. Strieter, M.D., 900 Veteran Avenue, 14-154 Warren Hall, P.O. Box 711922, David Geffen School of Medicine at UCLA, Los Angeles, CA 90024-1922. E-mail: rstrieter{at}mednet.ucla.edu

In a recent study of IFN-{gamma} 1b in 330 patients with idiopathic pulmonary fibrosis (IPF), progression-free survival was unchanged; however, a trend toward lower mortality was seen in IFN-{gamma} 1b–treated patients compared with placebo-treated patients (9.9 vs. 16.7%; p = 0.08). The purpose of this randomized, double-blind, placebo-controlled trial was to characterize molecular effects of subcutaneous IFN-{gamma} 1b (200 µg) thrice weekly for 6 months versus placebo in 32 patients with IPF. Messenger RNA in transbronchial lung biopsies and bronchoalveolar lavage cell pellet and protein levels in bronchoalveolar lavage fluid (BALF) and plasma were evaluated. After IFN-{gamma} 1b treatment, IFN-inducible T cell-{alpha} chemoattractant/CXCL11 (a chemokine with immunomodulatory, antiangiogenic, and defensin-like antimicrobial properties) increased in BALF (p = 0.016) and plasma (p < 0.001); BALF levels of epithelial neutrophil-activating protein-78/CXCL5 (p = 0.054), platelet-derived growth factor A (p = 0.033), and Type I procollagen (p = 0.096) were lower; and IFN-{gamma} levels were higher (p = 0.093) versus placebo. For messenger RNA in transbronchial biopsies, trends (p > 0.05 and <= 0.10) associated with IFN-{gamma} 1b treatment included an increase in IFN-inducible T cell-{alpha} chemoattractant/CXCL11, a decrease in elastin, and smaller increases for Type III procollagen and platelet-derived growth factor B. Changes in biomarkers of fibrosis, angiogenesis, proliferation, immunomodulation, and antimicrobial activity suggest that IFN-{gamma} 1b may affect IPF through multiple pathways.

Key Words: IFN-{gamma} 1b • proteins • pulmonary fibrosis • RNA




This article has been cited by other articles:


Home page
 Am. J. Respir. Crit. Care Med.Home page
S. Garantziotis, E. Zudaire, C. S. Trempus, J. W. Hollingsworth, D. Jiang, L. H. Lancaster, E. Richardson, L. Zhuo, F. Cuttitta, K. K. Brown, et al.
Serum Inter-{alpha}-Trypsin Inhibitor and Matrix Hyaluronan Promote Angiogenesis in Fibrotic Lung Injury
Am. J. Respir. Crit. Care Med., November 1, 2008; 178(9): 939 - 947.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
T J Williams and J W Wilson
Challenges in pulmonary fibrosis: 7 {middle dot} Novel therapies and lung transplantation
Thorax, March 1, 2008; 63(3): 277 - 284.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
C. J. Scotton and R. C. Chambers
Molecular Targets in Pulmonary Fibrosis: The Myofibroblast in Focus
Chest, October 1, 2007; 132(4): 1311 - 1321.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
C. A. Feghali-Bostwick, C. G. Tsai, V. G. Valentine, S. Kantrow, M. W. Stoner, J. M. Pilewski, A. Gadgil, M. P. George, K. F. Gibson, A. M. K. Choi, et al.
Cellular and Humoral Autoreactivity in Idiopathic Pulmonary Fibrosis
J. Immunol., August 15, 2007; 179(4): 2592 - 2599.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
S. D. Nathan, P. W. Noble, and R. M. Tuder
Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension: Connecting the Dots
Am. J. Respir. Crit. Care Med., May 1, 2007; 175(9): 875 - 880.
[Abstract] [Full Text] [PDF]

Home page
 QJMHome page
O.J. Dempsey, K.M. Kerr, L. Gomersall, H. Remmen, and G.P. Currie
Idiopathic pulmonary fibrosis: an update
QJM, October 1, 2006; 99(10): 643 - 654.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
K. M. Antoniou, A. G. Nicholson, M. Dimadi, K. Malagari, P. Latsi, A. Rapti, N. Tzanakis, R. Trigidou, V. Polychronopoulos, and D. Bouros
Long-term clinical effects of interferon gamma-1b and colchicine in idiopathic pulmonary fibrosis
Eur. Respir. J., September 1, 2006; 28(3): 496 - 504.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
C. Agostini and C. Gurrieri
Chemokine/Cytokine cocktail in idiopathic pulmonary fibrosis.
Proceedings of the ATS, January 1, 2006; 3(4): 357 - 363.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
R. M. Strieter
Pathogenesis and Natural History of Usual Interstitial Pneumonia: The Whole Story or the Last Chapter of a Long Novel
Chest, November 1, 2005; 128(5_suppl_1): 526S - 532S.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
S. D. Nathan
Therapeutic Intervention: Assessing the Role of the International Consensus Guidelines
Chest, November 1, 2005; 128(5_suppl_1): 533S - 539S.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
D. Bouros and K. M. Antoniou
Current and future therapeutic approaches in idiopathic pulmonary fibrosis
Eur. Respir. J., October 1, 2005; 26(4): 693 - 703.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
M. A Pacanowski and G. W Amsden
Interferon Gamma-1b in the Treatment of Idiopathic Pulmonary Fibrosis
Ann. Pharmacother., October 1, 2005; 39(10): 1678 - 1686.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
E. K. Bajwa, N. T. Ayas, M. Schulzer, E. Mak, J. H. Ryu, and A. Malhotra
Interferon-{gamma}1b Therapy in Idiopathic Pulmonary Fibrosis: A Metaanalysis
Chest, July 1, 2005; 128(1): 203 - 206.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
T. D. Bradley, Y. E. Miller, F. J. Martinez, D. C. Angus, W. MacNee, and E. Abraham
Interstitial Lung Disease, Lung Cancer, Lung Transplantation, Pulmonary Vascular Disorders, and Sleep-disordered Breathing in AJRCCM in 2004
Am. J. Respir. Crit. Care Med., April 1, 2005; 171(7): 675 - 685.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. D. Burdick, L. A. Murray, M. P. Keane, Y. Y. Xue, D. A. Zisman, J. A. Belperio, and R. M. Strieter
CXCL11 Attenuates Bleomycin-induced Pulmonary Fibrosis via Inhibition of Vascular Remodeling
Am. J. Respir. Crit. Care Med., February 1, 2005; 171(3): 261 - 268.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. P. Keane
Chemokine Profiling in Pulmonary Fibrosis: Ready for Prime Time?
Am. J. Respir. Crit. Care Med., September 1, 2004; 170(5): 475 - 476.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
J. H. Dauber, K. F. Gibson, and N. Kaminski
Interferon-{gamma} 1b in Idiopathic Pulmonary Fibrosis: What We Know and What Must We Learn
Am. J. Respir. Crit. Care Med., July 15, 2004; 170(2): 107 - 108.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2004 American Thoracic Society 		  New Orleans Int'l Conf